Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease

Exclusion Criteria

• •1. Female participants that are pregnant or of childbearing potential.
• •2. Unstable medical conditions for three months prior to screening visit such as poorly controlled blood pressure, diabetes, or breathing problems…etc.
• •3. Clinically significant abnormalities on liver, kidney or other blood tests
• •4. Significant neurologic disease such as Alzheimer's disease, Parkinson's disease, stroke, brain tumor, multiple sclerosis or seizure disorder.
• •5. Major depression in past 12 months (DSM-IV criteria), major mental illness such as schizophrenia, or recent (in past 12 months) alcohol or substance abuse.
• •6. History of invasive cancer within the past two years.
• •7. Contra-indications to lumbar puncture (bleeding disorder, platelet count \< 100,000, anticoagulant treatment, major structural abnormality or sepsis in the area of the lumbosacral spine that would make a lumbar puncture technically difficult).
• •8. Use of any investigational agents within 30 days prior to screening.
• •9. Contra-indications to MRI (metallic implants, pacemaker, shrapnel, ect…)
• •10. Sensitivity, intolerance, or allergies to gemfibrozil or any previous reaction to any cholesterol lowering medicine.
• •11. Major surgery within eight weeks prior to the Baseline Visit.
• •12. Blindness, deafness, language difficulties or any other disability which may prevent the potential participant from participating or cooperating in the protocol.
• •13. Physically unacceptable for this study as confirmed by medical history, physical exam, neurological exam and clinical tests.
• •* Exceptions to these criteria may be considered on a case-by-case basis, at the discretion of the examining study physician.
• •Excluded Medications:
• •1. Experimental drugs
• •2. Repaglinide
• •3. "Statins" including but not limited to atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor), pravastatin (Pravachol), rosuvastatin (Crestor), simvastatin (Zocor), or any combination medicines containing these drugs.
• •4. Coumadin, warfarin, heparin, lovenox, Xarelto, apixaban or other anticoagulants. (Antiplatelet therapy is acceptable).
• •NOTE: If these drugs are discontinued 4 weeks or more before screening, then the participant can be eligible for the study.